CTCA in children with severe heterozygous familial hypercholesterolaemia: Screening for subclinical atherosclerosis

Reijman, M. Doortje; van den Bosch, Sibbeliene E.; Kusters, D. Meeike; Corpeleijn, Willemijn E.; Hutten, Barbara A.; Kuipers, Irene M.; Planken, R. Nils; Wiegman, Albert

doi:10.1016/j.athplu.2023.12.002

Atherosclerosis Plus

2024

DOI: 10.1016/j.athplu.2023.12.002

|View full text |Cite

CTCA in children with severe heterozygous familial hypercholesterolaemia: Screening for subclinical atherosclerosis

M. Doortje Reijman,

Sibbeliene E. van den Bosch,

D. Meeike Kusters

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Familial hypercholesterolemia in children and the importance of early treatment

van den Bosch,

Hutten,

Corpeleijn

et al. 2024

Current Opinion in Lipidology

Self Cite

View full text Add to dashboard Cite

Purpose of review Familial hypercholesterolemia leads to elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth onwards due to a pathogenetic variation in genes in cholesterol metabolism. Early screening to identify and subsequently treat children with familial hypercholesterolemia is crucial to reduce the risk of premature atherosclerotic cardiovascular disease (ASCVD). This review focuses on recent insights in the field of pediatric familial hypercholesterolemia. Recent findings Screening in childhood and early initiation of optimal lipid-lowering therapy (LLT) have shown promising outcomes in the prevention of ASCVD. In addition, cost-effectiveness research has demonstrated highly favorable results. With the availability of novel therapies, familial hypercholesterolemia has become a well treatable disease. Summary Children with familial hypercholesterolemia benefit from early detection and optimal treatment of their elevated LDL-C levels.

show abstract

Familial hypercholesterolemia in children and the importance of early treatment

van den Bosch,

Hutten,

Corpeleijn

et al. 2024

Current Opinion in Lipidology

Self Cite

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

CTCA in children with severe heterozygous familial hypercholesterolaemia: Screening for subclinical atherosclerosis

Cited by 1 publication

References 13 publications

Familial hypercholesterolemia in children and the importance of early treatment

Familial hypercholesterolemia in children and the importance of early treatment

Contact Info

Product

Resources

About